Drug Type Mesenchymal stem cell therapy |
Synonyms aMBMC(Medstar Health Research Institute) |
Target- |
Mechanism Stem cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myocardial Ischemia | Phase 2 | US | 03 May 2019 | |
Non-ischemic Cardiomyopathy | Phase 2 | US | 03 May 2019 |
Phase 2 | 4 | (Human Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)) | nuniximkkm(eupgwlcxyt) = cgtwoinzyh vtikwfsbwl (cvngectrcx, ljhpdufncc - abxtfveugb) View more | - | 02 Feb 2022 | ||
Placebo (Placebo) | nuniximkkm(eupgwlcxyt) = wtaijnxhqy vtikwfsbwl (cvngectrcx, sekvlgyeso - szgdpcgqbt) View more |